What is Serva?
Serva operates at the intersection of advanced nuclear technology and sustainable energy production. By specializing in the development of innovative nuclear materials, the company addresses critical gaps in both the healthcare and energy sectors. Their core competency lies in the production of radioisotopes for oncology treatments and the engineering of advanced nuclear fuels designed to optimize reactor safety and efficiency. Through its Smart Nuclear Materials platform, Serva is effectively transforming nuclear waste into a viable resource, positioning itself as a key player in the global transition toward carbon-neutral power generation and precision medical diagnostics.
How much funding has Serva raised?
Serva has raised a total of $2.5M across 1 funding round:
Private Equity
$2.5M
Private Equity (2026): $2.5M, investors not publicly disclosed
Key Investors in Serva
Undisclosed Investor
An undisclosed institutional partner providing strategic capital to support the scaling of advanced nuclear material technologies.
What's next for Serva?
Following this major strategic investment, Serva is expected to scale its operational capacity to meet the growing demand for high-purity radioisotopes and next-generation fuel solutions. The company will likely prioritize the commercialization of its Smart Nuclear Materials, focusing on regulatory milestones and infrastructure expansion. As the firm transitions into this growth phase, the focus will shift toward establishing long-term partnerships with reactor operators and healthcare providers, ensuring that their technological advancements are integrated into the global energy grid and clinical supply chains. This capital infusion provides the necessary runway to solidify Serva's market leadership in the nuclear innovation space.
See full Serva company page
